Disulfiram was the first pharmacotherapy approved to treat alcohol use disorder in the 1950s. Disulfiram alters ethanol pharmacokinetics and causes uncomfortable reactions (e.g. headache, tachycardia, nausea, flushing and hypotension) when alcohol is consumed. Subsequently, a better understanding of the neurobiological pathways involved in alcohol use disorder led to the development of other medications (e.g. naltrexone and acamprosate). These neurobiological-based medications act on alcohol use disorder-related phenotypes including craving, stress, and/or withdrawal. The original approach to treat alcohol use disorder, by altering ethanol pharmacokinetics has been much less investigated. Recent research on ethanol pharmacokinetics has shed light on the mechanisms of action underlying alcohol use disorder and how some medications that alter ethanol pharmacokinetics may be helpful in treating alcohol use disorder. This review summarizes and discusses the complex pharmacokinetics of ethanol, and proposes that altering ethanol pharmacokinetics via novel pharmacological approaches may be a viable approach to treat alcohol use disorder.
Introduction
Alcohol use disorder (AUD) is a complex medical disease with dramatic consequences to our society in terms of mortality and morbidity (Rehm et al., 2010) . Research efforts have focused on different strategies to treat AUD (Edwards et al., 2011) including the development of medications to treat AUD. Pharmacological interventions to treat AUD may act by reversing the acute effects of ethanol (amethysic treatment), mitigating craving (urge to drink), and reducing stress and/or withdrawal (negative symptoms). Disulfiram was the first drug approved in the USA for the treatment of AUD, and today it is the only medication used clinically whose mechanism of action is based on altering ethanol pharmacokinetics.
This review describes the complexity of drug-ethanol interactions and discusses medications used to treat AUD that share pharmacokinetics pathways with ethanol. Critically, this review highlights possible pharmacological interventions for AUD that target ethanol-drug interactions without causing the overwhelming disulfiram-like adverse reactions to ethanol. This approach opens the possibility that exploring medications that alter ethanol pharmacokinetics may modulate biobehavioral effects of ethanol and improve drinking outcomes.
Overview of drug-ethanol interactions
Drug-drug interactions contribute significantly to adverse drug reactions (Pirmohamed et al., 2004) . They occur when the expected effects of a medication are enhanced or diminished by the administration of another medication. Drug-drug interactions can result in therapeutic failure (e.g. lower seizure threshold for phenytoin) and/or adverse events due to potentiation of their pharmacological effects (e.g. bleeding for warfarin).
Ethanol can also influence the effect of a drug by increasing the risk and/or exacerbating side-effects caused by the drug when used alone (e.g. hepatotoxicity for acetaminophen; gastrointestinal ulcers and/or bleeding for nonsteroidal anti-inflammatory drugs).
In most cases, pharmacokinetics interactions between ethanol and other drugs are unintended and should be avoided (Breslow et al., 2015) . On the other hand, there may be beneficial drugdrug interactions that could be used in clinical practice. For example, the co-formulated lopinavir/ritonavir led to the development of a gold standard combination antiretroviral therapy (Sham et al., 1998) , since ritonavir inhibits Cytochromes P450 (CYP) metabolism to improve the bioavailability of protease inhibitors. Although this strategy has never been evaluated or applied clinically to the treatment of AUD patients, targeting ethanol pharmacokinetics might hold promise for the development of future medications in the AUD field.
Medication development for AUD by using ethanol-drug interaction
Historically, AUD treatments have targeted complete abstinence from ethanol. Although disulfiram was developed as a pharmacological intervention that would facilitate abstinence, it is an approach that uses a therapeutically intended ethanol-drug interaction to deter individuals from consuming ethanol. More recently, it has been suggested that while alcohol abstinence remains the ideal therapeutic outcome to achieve, a reduction in alcohol drinking below harmful levels may be a beneficial goal for AUD individuals. An analysis that evaluated two large clinical trials demonstrated the utility of adopting the percent subjects with no heavy drinking days as a clinically informative end point measure (Falk et al., 2010) . The development of medications that target reduction of alcohol consumption, rather than complete abstinence, represents a novel pharmacological approach to facilitate reduction of alcohol drinking to below harmful levels. As such, altering ethanol pharmacokinetics parameters, without producing overwhelming adverse reactions, like disulfiram, may represent a novel target to treat AUD.
Pharmacological approaches that target ethanol metabolism via acetaldehyde dehydrogenase inhibition
The use of a compound able to produce aversive effects after concurrent consumption of ethanol was first suggested by a physician working in a rubber plant (Williams, 1937) . Subsequently, it was proposed that an amethysic compound can be utilized as a pharmacotherapy for alcoholism (Hald and Jacobsen, 1948) . The aversive approach was developed based on the idea that severe reaction to ethanol consumption would increase the patient's motivation to remain abstinent. The effect of disulfiram is to inhibit acetaldehyde dehydrogenase (ALDH), causing acetaldehyde to accumulate after alcohol intake, resulting in an immediate feeling of nausea after alcohol intake. Initial research on active metabolites of disulfiram suggests that its metabolites may inhibit ALDH with fewer adverse effects than the parent disulfiram (Madan and Faiman, 1994) . The metabolic products of disulfiram mediate the molecular mechanisms of ALDH by irreversible inhibition (covalent binding to the enzyme). However, glutathione is able to diminish this inhibition in less potent metabolites, while it does not affect inhibition in the more potent ones (Mays et al., 1998) . In addition, disulfiram is more potent for ALDH1A1 than ALDH2. Together, this observation raises the possibility that reversible inhibition via ALDH2 analogs (mediating specific, non-covalent interaction) may be a better pharmacological approach for AUD (Koppaka et al., 2012) .
Furthermore, selective ALDH2 inhibitors (e.g. ALDH2i) have been shown to be suitable for addiction since they prevent the increase of alcohol-induced rewarding dopamine release in the brain (Arolfo et al., 2009 ) and induce a decrease in norepinephrine release, which results in reduced excitation of dopaminergic neurons and reduced cocaine-induced euphoria in rats (Yao et al., 2010) . Finally, highly selective and reversible ALDH2 inhibitors exhibit anxiolytic properties in animal models of anxiety-like behavior ), a critical treatment component since feelings of anxiety can be prevalent during ethanol withdrawal and relapse (Lukas et al., 2013; Shen et al., 2012) .
Peripheral acetaldehyde accumulation is a deterrent for alcohol consumption while brain (rather than liver) ALDH functionality closely correlates with ethanol preference (Amir, 1978) . The brain itself can generate acetaldehyde from ethanol through three pathways: catalase (60%), CYP2E1 (20%) and alcohol dehydrogenase (ADH) (20%) ( Figure 1) ; for review see Hipolito et al. (2007) . Alcohol preference may result from acetaldehyde produced in the ventral tegmental area, via catalase, which has shown to have rewarding properties (Karahanian et al., 2011) . Since there is a putative contribution of brain acetaldehyde to ethanol tolerance and addiction (Deng and Deitrich, 2008) , reducing acetaldehyde levels in the brain may have therapeutic benefit for AUD.
Liver generated acetaldehyde also enters in the brain; however, it cannot reach considerable levels mostly due to the presence of ALDH in the microvasculature of the blood brain barrier (Eriksson and Sippel, 1977; Westcott et al., 1980) . Acetaldehyde possesses reinforcing properties (Karahanian et al., 2011) , suggesting that some ethanol-induced behavioral effects may be a Figure 1 . Pharmacological approaches that target ethanol metabolism via ALDH inhibition. Non selective irreversible inhibition of ALDH (disulfiram) produces aversive side-effects. Selective ALDH2 reversible inhibition (ALDH2i) has been shown to prevent the increase of alcoholinduced rewarding dopamine release in brain, reduce cocaine-induced euphoria, and inhibit anxiety-like behaviors. ADH: alcohol dehydrogenase; ALDH: acetaldehyde dehydrogenase; ALDH2i: ALDH2 reversible inhibitor result of the formation of acetaldehyde. Interestingly, acetaldehyde injected directly in rodent brains produces ethanol-induced like behaviors (Quintanilla et al., 2002; Rodd et al., 2005; Smith et al., 1984) . Preclinical studies have highlighted the importance of considering modulating ethanol pharmacokinetics by inhibiting its metabolism with consequent acetaldehyde accumulation selectively at central (positive reinforcing) levels (Guerrini et al., 2006; Imbert et al., 2015; Kerr et al., 1989; Keung and Vallee, 1993) . In the brain, where catalase is the primary ethanolmetabolizing enzyme, ALDH2 is expressed at very low levels. Therefore, modulation of brain catalase activity can change acetaldehyde levels, and possibly influence ethanol-related addictive behaviors. All these observations support the hypothesis that acetaldehyde in the brain may play a role in AUD (Deng and Deitrich, 2008) . Therefore, while irreversible inhibition of ALDH2 by disulfiram represents a treatment based on ethanol aversion, selective inhibition of ALDH2, or catalase, in the brain should be further evaluated as a possible new pharmacological central nervous system approach to probe a pharmacokineticsbased approach to treat AUD. The exact mechanism for acetaldehyde's behavioral effects, however, is still under investigation, at this stage, and the hypothesis that modulating brain acetaldehyde can be beneficial for treating AUD requires further research and clinical exploration.
Pharmacological approaches that can reduce ethanol cytotoxic effects
Altering ethanol pharmacokinetics may represent an effective approach for reducing the toxic tissue and organ effects of both acute and chronic exposure to alcohol. Metadoxine, a pyridoxine-pyrrolidone carboxylate, is a medication approved in several European countries (but not in the USA) for treating alcohol intoxication. Metadoxine has also been evaluated as a medication effective to reduce the cytotoxic effects of ethanol. In cell culture, metadoxine prevented glutathione depletion, increased collagen, and reduced ethanol-induced lipid peroxidation damage and tumor necrosis factor-α secretion caused by acetaldehyde production (Gutierrez-Ruiz et al., 2001) (Figure 2 ). Metadoxine appeared to inhibit CYP2E1 (Ki et al., 2007) , a specific ethanolinducible liver isoenzyme (Dey and Cederbaum, 2006) involved in liver injury (steatosis and steatohepatitis) after chronic ethanol ingestion (Ardies et al., 1987) . These data support early preclinical studies on ethanol-exposed rats, where pyridoxidine reversed the reduction in the apoenzyme for tryptophan pyrrolase caused by chronic ethanol exposure (Ragusa et al., 1980) . Notably, clinical studies support a role of metadoxine in reducing alcoholrelated tissue damage, specifically in alcoholic liver disease (Caballeria et al., 1998; Higuera-de la Tijera et al., 2015) .
Metadoxine appears to accelerate ethanol metabolism by increasing the activity of ALDH and by accelerating plasma and urinary clearance of ethanol (Calabrese et al., 1995; Pares et al., 1991) . Furthermore, in a double-blind, randomized controlled trial with patients with acute ethanol intoxication a single intravenous administration of metadoxine, compared with placebo, significantly increased ethanol elimination and decreased blood alcohol content (BAC) (Shpilenya et al., 2002) . This also resulted in decreased symptoms of ethanol intoxication (e.g. agitation, impairment). Additionally, preliminary clinical data suggest that metadoxine may reduce alcohol drinking in alcohol-dependent individuals (Guerrini et al., 2006; Leggio et al., 2011) . However, the data generated until now are very preliminary and the possible mechanisms of action of how metadoxine may work are not fully understood. Therefore, additional work is needed to evaluate metadoxine and other novel pharmacotherapies that may be beneficial in reducing alcohol use by modulating ethanol pharmacokinetics.
Another strategy to reduce the cytotoxic effect of alcohol focuses on the utilization of energy substrate in the brain. Early brain imaging studies have shown that alcohol-induced decreases in brain activity (de Wit et al., 1990; Volkow et al., 1990 ) may be due to the effect of alcohol in decreasing glucose metabolism (Volkow et al., 2006) . More recently, a positron emission tomography study showed that during heavy alcohol consumption there is a shift from brain glucose metabolism to acetate or other ketones (Jiang et al., 2013; Volkow et al., 2013) . As such the use of acetate, as an alternative energy substrate during acute intoxication, was seen as a vulnerable pathophysiological effect during alcohol intoxication and replacement during withdrawal. The sudden deprivation of brain glucose (favored energy substrate) and acetate (alternative energy substrate) may contribute to the negative symptoms during alcohol withdrawal. This withdrawal effect raises the possibility of a therapeutic intervention where increasing plasma acetate concentration (ketogenic diet) could help minimize adverse effects from acute alcohol withdrawal in alcohol abusers undergoing detoxification (Volkow et al., 2015) .
Pharmacological approaches that target the biphasic effects of ethanol
A pharmacotherapy for AUD able to alter ethanol pharmacokinetics might represent an interesting mechanism to facilitate reduction in ethanol use by altering the pleasurable acute effects ADH: alcohol dehydrogenase; ALDH: acetaldehyde dehydrogenase; BAC: blood alcohol content; TNF-α: tumor necrosis factor-α of ethanol. Alcohol consumption influences executive cognitive functioning differentially on the ascending, compared with the descending, limb of the BAC curve (Pihl et al., 2003) . As such, the co-administration of a medication for AUD with ethanol should ideally affect the biphasic effects of ethanol by reducing the stimulant and/or increasing the sedative effects in the alcohol ascending limb. For example, the FDA-approved medication naltrexone has shown to reduce the stimulant effects of alcohol (Setiawan et al., 2011; Swift et al., 1994) . Naltrexone seems to mediate this effect by disrupting the connection between alcohol-induced stimulation and further alcohol consumption (Anton et al., 2004) .
Recently, a double-blind, placebo-controlled, human laboratory pilot study evaluated ethanol pharmacokinetics when co-administered with idazoxan, an α 2 -adrenergic antagonist (Haass-Koffler et al., 2015) . This study showed that a single dose of idazoxan (40 mg) produced a reduction of peak concentration (C max ) and delay of time of maximum concentration (t max ), and altered the biphasic effects of ethanol by decreasing stimulation and increasing sedation in social drinkers. A pharmacokinetics/pharmacodynamics (PK/PD) model that linked ethanol concentration (pharmacokinetics) and ethanol effects (pharmacodynamics) (Wright et al., 2011) was used to evaluate ethanol dose-concentration-response relationships after medication administration (Holford, 1997; Taylor et al., 2008) . The PK/PD model adopted in this study (Haass-Koffler et al., 2015) was useful since pharmacokinetics levels (C max and t max ) and pharmacodynamics symptoms (stimulation effects) influence each other. While reduction of C max may represent the reduction of BAC, delayed t max typically accompanies delays in gastric emptying (Wright et al., 2011) (Figure 3) . The pharmacokinetics effects of idazoxan may be due to the selective activation of the α 2A -adrenoceptor subtype, which has been shown to be responsible for the inhibition of gastric emptying in preclinical models (Tsukada et al., 2003) , thereby reducing ethanol bioavailability.
Pharmacological approaches with additional effects on alcohol pharmacokinetics
A variety of antioxidant isoflavones (puerarin, daidzin, and daidzein), extracted from the kudzu plant (Pueraria lobata), have been used as antidipsotropic treatments in Chinese medicine; for review see McGregor (2007) . Daidzin is a highly potent inhibitor of the ALDH2 isozyme (IC 50 , 80-nM) (Lowe et al., 2008) . It also seems to reduce BAC levels by a delay of stomach emptying in rats (Lin and Li, 1998) . Other daidzin analogs have been developed with more selective and reversal inhibitors specifically for ALDH2 (Arolfo et al., 2009 ). These compounds have also been shown to reduce ethanol consumption and increase abstinence in non-treatment-seeking heavy drinkers (Lukas et al., 2013; Penetar et al., 2012) .
Another flavonoid, dihydromyricitin, a compound purified from the plant Hovenia, has also been used in traditional Chinese medicine for treating alcohol abuse. Dihydromyricitin also appears to antagonize alcohol effects, although less is known about its mechanism of action (Shen et al, 2012) . Other flavonoids compounds, including genistein and resveratrol, may reduce alcoholic fatty liver (Tang et al., 2016) and have been studied for the treatment of AUD for years.
Challenges in medication development that alter ethanol pharmacokinetics
Pharmacological interventions that alter ethanol pharmacokinetics, without producing the disulfiram adverse reaction to alcohol, might represent a novel approach to evaluate AUD pharmacotherapies. However, there are several clinical challenges with this approach.
First, pharmacokinetics pathways are very difficult to assess accurately in a heterogeneous AUD population. One of the main sources of inter-individual variability in ethanol metabolism is the genetic polymorphisms in the ethanol metabolizing enzymes (Li et al., 2001) . There are five functional classes of cytosolic ADH encoded by seven human genes. Polymorphism occurs at the ADH2 and ADH3 loci, which account for the significant differences in alcohol metabolism observed in different ethnic and racial groups: ADH2*1 (White and Black), ADH2*2 (Asian), and ADH2*3 (~15% African-American). Compared with the more common ADH2*1 allele, the ADH2*3 isozyme has a higher metabolic rate, which may result in a protective effect. Polymorphisms also occur at mitochondrial ALDH. Approximately one-third of Asians possess a slow variant of ALDH (ALDH*2) that results in accumulation of acetaldehyde, producing the uncomfortable flushing due to vasodilation (Higuchi et al., 1995; Takeshita and Morimoto, 2000) .
Medications that affect alcohol metabolism have so far shown limited efficacy in clinical practice. Clinical trials of disulfiram have yielded negative results (Fuller and Gordis, 2004; Jonas et al., 2014; Jorgensen et al., 2011) . Variability in medication compliance and responses to acetaldehyde accumulation between individuals (Substance Abuse and Mental Health Services Administration, 2009) introduces inconsistent patient response to treatment using this approach. The variable acetaldehyde response produced by disulfiram appears to be due to the fact that disulfiram is a pro-drug that has to be enzymatically converted to active metabolites, notably N-acetyl-S-(N,N-diethylcarbamoyl) cysteine and the amount of this metabolite produced varies across individuals (Winefield et al., 2015) . Altering the function of alcohol metabolizing enzymes can have other effects, as ethanol is not the exclusive substrate of these enzymes. ADH enzymes interact with many different molecules depending on the enzymes' location within the cell. For example, ADH and ALDH are involved in retinoic acid synthesis and metabolism. Interestingly, ADH enzymes are primarily found in liver and kidney cells, but are also expressed in other cells throughout the body. Within cells, ADH enzymes are located in the endoplasmic reticulum (protein processing and transport), mitochondria (energy), cytosol (cellular internal fluid), and the nucleus. As such, any manipulation affecting acetaldehyde accumulation should be considered carefully, since acetaldehyde accumulation is connected with serious pathologies including cancers and neurodegenerative diseases; for an extensive review, see Chen et al. (2014) .
The downside of developing medications that can reduce BAC is a potential misuse of these medications in binge drinking individuals. For example, on college campuses, students, or drivers, could use such a drug before a binge drinking episode and effect a high level of ethanol consumption without reaching the BAC levels considered to legally define being drunk. Therefore, while pharmacotherapies for AUD that lower BAC levels may be beneficial by reducing tissue chemical toxicity and by lowering the intoxication effect, this effect may encourage drinkers to consume more ethanol to achieve the expected pleasurable effects. A combined biobehavioral model that assesses alcohol concentration (pharmacokinetics) and alcohol effects (pharmacodynamics) (Wright et al., 2011) should be developed to provide a conceptual framework in human studies. A PK/PD paradigm may be helpful to evaluate ethanol doseconcentration-response relationships (Haass-Koffler et al., 2015; Holford, 1997; Taylor et al., 2008) . Finally, in addition to the heterogeneity of this disease (early versus late onset of alcoholism, comorbidities, severe withdrawal, etc.), the pharmacokinetics parameters (absorption, distribution, metabolism, and excretion) and variations between individuals may present a significant challenge for developing medications that target ethanol pharmacokinetics.
Conclusion
Disulfiram, the first medication approved by the FDA for AUD, acts via altering ethanol metabolism. The use of disulfiram for AUD, however, has generated conflicting results in clinical practice and a recent meta-analysis does not support its efficacy for AUD patients (Jonas et al., 2014) . However, medications that alter ethanol pharmacokinetics, without the adverse symptoms when co-administered with alcohol, may represent a novel approach to elucidate the complex mechanisms of AUD and develop novel therapeutic approaches. For example, selective ALDH2 reversible inhibitors have been evaluated as potential novel approaches for the treatment of AUD. Also, the use of medications that reduce BAC would limit the delivery of chronic ethanol chemical toxic effects at the tissue level and would reduce the undesirable behavioral effects produced by acute intoxication. Finally, incorporating pharmacokinetics parameters into neurobiological analyses may shed light on the positive/ stimulant effects of ethanol.
While manipulating ethanol pharmacokinetics represents an intriguing and potentially exciting approach to investigate novel medications for AUD, there are several challenges with this approach that must be taken into account, including (but not limited to) the genetic variability in the enzymes that affect ethanol metabolism, the variability in the time between ethanol ingestion and medication response between individuals, and the potential risk of excessive alcohol use to overcome the effects of the putatively effective medication.
